I expect that the shear volume, this year, of prospective catalysts for a re-rate will have the desired effect.
For instance, unless there has been an unexpected delay, an announcement about completion of recruitment for the SynPath ulcer trial is imminent, with study completion to follow after 12 weeks.
At the very least, starting with the upcoming 1HY results, CAGRs of over 40% cannot be ignored for too long.
I expect that the shear volume, this year, of prospective...
-
- There are more pages in this discussion • 1,592 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
-0.055(2.26%) |
Mkt cap ! $1.657B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.43 | $2.37 | $1.106M | 462.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 49900 | $2.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 17826 | 36 |
View Market Depth
| Last trade - 15.05pm 16/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |